In vivo treatment with high-dose sorafenib may have negative effects on the immune microenvironment, such as an increase in PD-L1 expression41, or recruitment of myeloid-derived suppressor cells42, regulatory T cells43 and tumor-associated macrophages44. Here, CD274 is linked to neoplasm.